App Profile: MyFibroScan
Android / Games / Puzzles
myFibroScan
Installs:
Rating:
2.82
Total Reviews:
11
Top Countries:
TH, US, FR
< $5k
/mo
< 5k
/mo
Reviews: What People Think About myFibroScan
962862
Rating: 1/5
This new update is weird. When looking at patients scores it does not properly say S3 OR S2. I need it to just say what it is.
Nickname 20,000
Rating: 1/5
App is buggy and unable to send me an email to validate my account so I can use it. It will however successfully send an message for password reset so the issue is not an incorrect email address. I’ve wasted over an hour on trying to get it to work.
MM1NJ
Rating: 1/5
App does not open on my iPhone 14, despite downloading it the second time and restarting my phone
About myFibroScan
FibroScan® is the non-invasive gold standard solution for comprehensive management of liver health.
FibroScan® is powered by three unique, patented and validated biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 5300+ peer-reviewed publications and 180+ international guidelines.
myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way :
The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting FibroScan® examination results.
Scores enhance FibroScan® liver disease assessment with biological markers.
Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.
• Fast is an aid to identify at risk MASH patients defined as MASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast.
• Agile 3+ is an aid to identify MASLD patients with advanced fibrosis by combining LSM by VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.
• Agile 4 is an aid to early identify MASLD patients with cirrhosis by combining LSM by VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.
MASH Treatment Eligibility Tool to eliminate the Guesswork.
This patient management tool embeds treatment recommendations based on the patient’s FibroScan® results and the latest AASLD Guidance.
FibroScan® is powered by three unique, patented and validated biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 5300+ peer-reviewed publications and 180+ international guidelines.
myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way :
The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting FibroScan® examination results.
Scores enhance FibroScan® liver disease assessment with biological markers.
Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.
• Fast is an aid to identify at risk MASH patients defined as MASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast.
• Agile 3+ is an aid to identify MASLD patients with advanced fibrosis by combining LSM by VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.
• Agile 4 is an aid to early identify MASLD patients with cirrhosis by combining LSM by VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.
MASH Treatment Eligibility Tool to eliminate the Guesswork.
This patient management tool embeds treatment recommendations based on the patient’s FibroScan® results and the latest AASLD Guidance.
File size: 41927680
Launched countries: FRAUCADEGBITJPKRRUDZAOARATAZBBBYBEBMBRBGCLCOCRHRCZDKDOECEGSVFIGHGRGTHKHUINIDIEILKZKEKWLBLTLUMOMGMYMXNLNZNGNOOMPKPAPEPHPLPTQAROSASGSKSIZAESLKSECHTWTHTNTRUAAEUYUZVEVNBOEELVNIPYKHMZYEBHCYMTBJBFCGJOLAMLSNTZUGZW
Minimum OS version: 15.6
Release Date: 1492376139000
Published by ECHOSENS
Website url: https://www.echosens.com/products/my-fibroscan/
Publisher country: France
